Abstract
Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer. Inclusion in the regimen of targeted drugs as trastuzumab (Herceptin) and pertuzumab significantly improves outcomes in HER2-positive breast cancer patients. A certain part of HER2-positive patients can be cured by using only targeted drugs without chemotherapy.
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / analysis*
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Chemotherapy, Adjuvant
-
Female
-
Humans
-
Inflammatory Breast Neoplasms / drug therapy
-
Lapatinib
-
Middle Aged
-
Molecular Targeted Therapy / methods*
-
Neoadjuvant Therapy / methods*
-
Quinazolines / administration & dosage
-
Receptor, ErbB-2 / analysis*
-
Trastuzumab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Biomarkers, Tumor
-
Quinazolines
-
Lapatinib
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
pertuzumab
-
Trastuzumab